International biobanking for lung cancer and COPD as thefuture resource for clinical protein research

Thomas E. Fehniger, Ákos Végvári, Melinda Rezeli, B. Döme, J. Tímár, György Marko-Varga

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Characterized tissue with pathological grading and blood samples as well as other biofluidsforms the basis for all biobanks as a resource in modern life science. Biobanks are accessed tomeasure biological components that can be used to monitor the status of health and diseasein individual samples and population groups. The biomarker diagnostics area, predictingdrug efficacy, stratification of patient groups, can benefit from the continuous qualitativedevelopments, where Proteomics can make a difference in lung cancer and COPD. This inturn can provide key treasures to novel drugs for personalized medicine in the future.

Original languageEnglish
Pages (from-to)3-7
Number of pages5
JournalEuPA Open Proteomics
Volume1
DOIs
Publication statusPublished - 2013

Fingerprint

Precision Medicine
Biological Science Disciplines
Biomarkers
Population Groups
Proteomics
Chronic Obstructive Pulmonary Disease
Health Status
Medicine
Lung Neoplasms
Blood
Health
Tissue
Research
Pharmaceutical Preparations
Proteins

Keywords

  • Biobank
  • COPD
  • Lung cancer
  • Pathologya

ASJC Scopus subject areas

  • Biochemistry

Cite this

International biobanking for lung cancer and COPD as thefuture resource for clinical protein research. / Fehniger, Thomas E.; Végvári, Ákos; Rezeli, Melinda; Döme, B.; Tímár, J.; Marko-Varga, György.

In: EuPA Open Proteomics, Vol. 1, 2013, p. 3-7.

Research output: Contribution to journalArticle

Fehniger, Thomas E. ; Végvári, Ákos ; Rezeli, Melinda ; Döme, B. ; Tímár, J. ; Marko-Varga, György. / International biobanking for lung cancer and COPD as thefuture resource for clinical protein research. In: EuPA Open Proteomics. 2013 ; Vol. 1. pp. 3-7.
@article{0833c1f46d6341428e042be3460f42d1,
title = "International biobanking for lung cancer and COPD as thefuture resource for clinical protein research",
abstract = "Characterized tissue with pathological grading and blood samples as well as other biofluidsforms the basis for all biobanks as a resource in modern life science. Biobanks are accessed tomeasure biological components that can be used to monitor the status of health and diseasein individual samples and population groups. The biomarker diagnostics area, predictingdrug efficacy, stratification of patient groups, can benefit from the continuous qualitativedevelopments, where Proteomics can make a difference in lung cancer and COPD. This inturn can provide key treasures to novel drugs for personalized medicine in the future.",
keywords = "Biobank, COPD, Lung cancer, Pathologya",
author = "Fehniger, {Thomas E.} and {\'A}kos V{\'e}gv{\'a}ri and Melinda Rezeli and B. D{\"o}me and J. T{\'i}m{\'a}r and Gy{\"o}rgy Marko-Varga",
year = "2013",
doi = "10.1016/j.euprot.2013.04.001",
language = "English",
volume = "1",
pages = "3--7",
journal = "EuPA Open Proteomics",
issn = "2212-9685",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - International biobanking for lung cancer and COPD as thefuture resource for clinical protein research

AU - Fehniger, Thomas E.

AU - Végvári, Ákos

AU - Rezeli, Melinda

AU - Döme, B.

AU - Tímár, J.

AU - Marko-Varga, György

PY - 2013

Y1 - 2013

N2 - Characterized tissue with pathological grading and blood samples as well as other biofluidsforms the basis for all biobanks as a resource in modern life science. Biobanks are accessed tomeasure biological components that can be used to monitor the status of health and diseasein individual samples and population groups. The biomarker diagnostics area, predictingdrug efficacy, stratification of patient groups, can benefit from the continuous qualitativedevelopments, where Proteomics can make a difference in lung cancer and COPD. This inturn can provide key treasures to novel drugs for personalized medicine in the future.

AB - Characterized tissue with pathological grading and blood samples as well as other biofluidsforms the basis for all biobanks as a resource in modern life science. Biobanks are accessed tomeasure biological components that can be used to monitor the status of health and diseasein individual samples and population groups. The biomarker diagnostics area, predictingdrug efficacy, stratification of patient groups, can benefit from the continuous qualitativedevelopments, where Proteomics can make a difference in lung cancer and COPD. This inturn can provide key treasures to novel drugs for personalized medicine in the future.

KW - Biobank

KW - COPD

KW - Lung cancer

KW - Pathologya

UR - http://www.scopus.com/inward/record.url?scp=84884583780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884583780&partnerID=8YFLogxK

U2 - 10.1016/j.euprot.2013.04.001

DO - 10.1016/j.euprot.2013.04.001

M3 - Article

AN - SCOPUS:84884583780

VL - 1

SP - 3

EP - 7

JO - EuPA Open Proteomics

JF - EuPA Open Proteomics

SN - 2212-9685

ER -